Preston Noon

Director/Board Member at ViTToria Biotherapeutics, Inc.

Finance

Consumer Services

Health Technology

Profile

Preston Noon is currently working as a Director at viTToria Biotherapeutics, Inc. and as a Partner at Agent Capital LLC.
He holds a Master's degree in Business Administration from the University of Connecticut.

Preston Noon active positions

Companies	Position	Start
Agent Capital LLC Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.	Private Equity Investor	-
ViTToria Biotherapeutics, Inc. ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation.	Director/Board Member	-

All active positions of Preston Noon

Training of Preston Noon

University of Connecticut

Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Preston Noon's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Agent Capital LLC Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.	Finance
ViTToria Biotherapeutics, Inc. ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation.	Health Technology